The inverse relationship between chronic HBV and HCV infections among injection drug users is associ

[Guest guest]

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2893.2008.01005.x

Journal of Viral Hepatitis

OnlineEarly Articles

doi:10.1111/j.1365-2893.2008.01005.x

Abstract

The inverse relationship between chronic HBV and HCV infections among injection

drug users is associated with decades of age and drug use

F.-C. Tseng11Division of Cancer Epidemiology and Genetics, National Cancer

Institute, Bethesda, MD, USA, B. R. Edlin2,32University of California, San

Francisco, CA, USA3Weill Medical College of Cornell University, New York, NY,

USA, M. Zhang11Division of Cancer Epidemiology and Genetics, National Cancer

Institute, Bethesda, MD, USA, A. Kral2,42University of California, San

Francisco, CA, USA4RTI International, San Francisco Regional Office, San

Francisco, CA, USA, M. P. Busch2,52University of California, San Francisco, CA,

USA5Blood Systems Research Institute, San Francisco, CA, USA, B. A.

Ortiz-Conde66Viral Oncology Section, AIDS Vaccine Program, SAIC-Frederick,

NCI-Frederick, Frederick, MD, USA, T. M. Welzel11Division of Cancer Epidemiology

and Genetics, National Cancer Institute, Bethesda, MD, USA and T. R.

O¡¯Brien11Division of Cancer Epidemiology and Genetics, National Cancer

Institute, Bethesda, MD, USA1Division of Cancer Epidemiology and Genetics,

National Cancer Institute, Bethesda, MD, USA; 2University of California, San

Francisco, CA, USA; 3Weill Medical College of Cornell University, New York, NY,

USA; 4RTI International, San Francisco Regional Office, San Francisco, CA, USA;

5Blood Systems Research Institute, San Francisco, CA, USA; and 6Viral Oncology

Section, AIDS Vaccine Program, SAIC-Frederick, NCI-Frederick, Frederick, MD, USA

R. O¡¯Brien, Division of Cancer Epidemiology and Genetics, National

Cancer Institute, Advanced Technology Center, Room 225A, MSC 4605 8717,

Grovemont Circle, Bethesda, MD 20892-4605, USA. E-mail: obrient@...

95% CI, 95% confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus;

IDU, injection drug user; HBsAg, hepatitis B surface antigen; HIV-1, human

immunodeficiency virus type 1; UHS, Urban Health Study.

Abstract

Summary. Infection with hepatitis C virus (HCV) may suppress co-infection with

hepatitis B virus (HBV) during acute or chronic HBV infection. We examined

relationships between HBV infection, HCV infection and other factors among

injection drug users (IDUs) with antibodies to both viruses. Participants

enrolled in a cross-sectional study during 1998¨C2000 were considered to have

been infected with HBV if they had core antibody, to be chronically infected if

they had hepatitis B surface antigen (HBsAg), to have been infected with HCV if

they had HCV antibody and to be chronically infected if they had HCV RNA. Among

1694 participants with antibody to both viruses, HBsAg prevalence decreased with

increasing age among those positive for HCV RNA [from 4.55% in those 18¨C29

years to 1.03% in those ¡Ý50 years old (Ptrend = 0.02)], but not among those who

were negative for HCV RNA. Chronic HBV infection was less common overall among

those with chronic HCV infection (odds ratio [OR], 0.25; P < 0.0001), but this

inverse relationship was much stronger in the oldest (>50 years; OR = 0.15) than

the youngest (18¨C29 years; OR = 0.81) participants (Ptrend = 0.03). Similar

results were obtained when duration of injection drug use was substituted for

age (Ptrend = 0.05). Among IDUs who have acquired both HBV and HCV, chronic HBV

infection is much less common among those with chronic HCV infection, but this

inverse relationship increases markedly with increasing years of age and

injection drug use. Co-infection with HCV may enhance the resolution of HBsAg

during the chronic phases of these infections.

_________________________________________________________________

Keep your kids safer online with Windows Live Family Safety.

http://www.windowslive.com/family_safety/overview.html?ocid=TXT_TAGLM_WL_Refresh\

_family_safety_052008

[Guest guest]

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2893.2008.01005.x

Journal of Viral Hepatitis

OnlineEarly Articles

doi:10.1111/j.1365-2893.2008.01005.x

Abstract

The inverse relationship between chronic HBV and HCV infections among injection

drug users is associated with decades of age and drug use

F.-C. Tseng11Division of Cancer Epidemiology and Genetics, National Cancer

Institute, Bethesda, MD, USA, B. R. Edlin2,32University of California, San

Francisco, CA, USA3Weill Medical College of Cornell University, New York, NY,

USA, M. Zhang11Division of Cancer Epidemiology and Genetics, National Cancer

Institute, Bethesda, MD, USA, A. Kral2,42University of California, San

Francisco, CA, USA4RTI International, San Francisco Regional Office, San

Francisco, CA, USA, M. P. Busch2,52University of California, San Francisco, CA,

USA5Blood Systems Research Institute, San Francisco, CA, USA, B. A.

Ortiz-Conde66Viral Oncology Section, AIDS Vaccine Program, SAIC-Frederick,

NCI-Frederick, Frederick, MD, USA, T. M. Welzel11Division of Cancer Epidemiology

and Genetics, National Cancer Institute, Bethesda, MD, USA and T. R.

O¡¯Brien11Division of Cancer Epidemiology and Genetics, National Cancer

Institute, Bethesda, MD, USA1Division of Cancer Epidemiology and Genetics,

National Cancer Institute, Bethesda, MD, USA; 2University of California, San

Francisco, CA, USA; 3Weill Medical College of Cornell University, New York, NY,

USA; 4RTI International, San Francisco Regional Office, San Francisco, CA, USA;

5Blood Systems Research Institute, San Francisco, CA, USA; and 6Viral Oncology

Section, AIDS Vaccine Program, SAIC-Frederick, NCI-Frederick, Frederick, MD, USA

R. O¡¯Brien, Division of Cancer Epidemiology and Genetics, National

Cancer Institute, Advanced Technology Center, Room 225A, MSC 4605 8717,

Grovemont Circle, Bethesda, MD 20892-4605, USA. E-mail: obrient@...

95% CI, 95% confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus;

IDU, injection drug user; HBsAg, hepatitis B surface antigen; HIV-1, human

immunodeficiency virus type 1; UHS, Urban Health Study.

Abstract

Summary. Infection with hepatitis C virus (HCV) may suppress co-infection with

hepatitis B virus (HBV) during acute or chronic HBV infection. We examined

relationships between HBV infection, HCV infection and other factors among

injection drug users (IDUs) with antibodies to both viruses. Participants

enrolled in a cross-sectional study during 1998¨C2000 were considered to have

been infected with HBV if they had core antibody, to be chronically infected if

they had hepatitis B surface antigen (HBsAg), to have been infected with HCV if

they had HCV antibody and to be chronically infected if they had HCV RNA. Among

1694 participants with antibody to both viruses, HBsAg prevalence decreased with

increasing age among those positive for HCV RNA [from 4.55% in those 18¨C29

years to 1.03% in those ¡Ý50 years old (Ptrend = 0.02)], but not among those who

were negative for HCV RNA. Chronic HBV infection was less common overall among

those with chronic HCV infection (odds ratio [OR], 0.25; P < 0.0001), but this

inverse relationship was much stronger in the oldest (>50 years; OR = 0.15) than

the youngest (18¨C29 years; OR = 0.81) participants (Ptrend = 0.03). Similar

results were obtained when duration of injection drug use was substituted for

age (Ptrend = 0.05). Among IDUs who have acquired both HBV and HCV, chronic HBV

infection is much less common among those with chronic HCV infection, but this

inverse relationship increases markedly with increasing years of age and

injection drug use. Co-infection with HCV may enhance the resolution of HBsAg

during the chronic phases of these infections.

_________________________________________________________________

Keep your kids safer online with Windows Live Family Safety.

http://www.windowslive.com/family_safety/overview.html?ocid=TXT_TAGLM_WL_Refresh\

_family_safety_052008